Sarah Merrick
Internal Medicine · Louisville, KYNPI 1922134311
Payments from drug & device makers
Across 145 payments — averaging $13.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$630
- AstraZeneca$318
- Lilly USA, LLC$268
- AbbVie$188
- GSK$130
- Amgen$109
- plus $320 from 12 others
What the payments were for
- Food & beverage$1,959100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $630 |
| AstraZeneca(2 entities) | 23 | $318 |
| Lilly USA, LLC | 19 | $268 |
| AbbVie | 11 | $188 |
| GSK | 9 | $130 |
| Amgen | 7 | $109 |
| Merck | 4 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Boehringer Ingelheim | 3 | $42 |
| Amarin Pharma, Inc. | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Johnson & Johnson | 2 | $27 |
| Philips North America LLC | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Novartis | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Eisai Inc. | 1 | $11 |
How this compares
$1,964 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $21,544 |
| JanuviaSitagliptin Phosphate | 11 | $16,064 |
| SynthroidLevothyroxine Sodium | 58 | $1,939 |
| Levothyroxine Sodium | 103 | $1,311 |
| Atorvastatin Calcium | 94 | $1,092 |
| Esomeprazole Magnesium | 18 | $760 |
| Omeprazole | 38 | $648 |
| Bupropion XlBupropion Hcl | 13 | $521 |
| Duloxetine Hcl | 27 | $482 |
| Lisinopril | 67 | $476 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $468 |
| Gabapentin | 35 | $409 |
| Montelukast Sodium | 35 | $406 |
| Losartan Potassium | 34 | $394 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $49 | $16,06411 claims |
| AbbVieSynthroid | $188 | $1,93958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Louisville
- Jason ChesneyLouisville$6.3M
- Robert SasserLouisville$62K
- Kelley McIntyreLouisville$48K
- Lal TanwaniLouisville$38K
- Mark WilliamsLouisville$33K
- Scott YoungLouisville$24K
- Frank SimonLouisville$22K
- Walter BruningLouisville$22K
- Brian ParadowskiLouisville$20K
- Suresh NairLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.